SK Biopharmaceuticals Co., Ltd. 326030.KS · Stock Open SK Biopharmaceuticals Co., Ltd. in new tab
SK Biopharmaceuticals Co., Ltd. Analysis (326030.KS)
Is SK Biopharmaceuticals Co., Ltd. a good investment? SK Biopharmaceuticals Co., Ltd. (326030.KS) is currently trading at 89100.00 KRW. Market analysts have a consensus price target of 137923.08 KRW. This suggests a potential upside from current levels.
Earnings Schedule: SK Biopharmaceuticals Co., Ltd. is expected to release its next earnings report on Aug. 11, 2026.
Investor FAQ
Does SK Biopharmaceuticals Co., Ltd. pay a dividend?
No, it does not currently pay a dividend.
What asset class is SK Biopharmaceuticals Co., Ltd.?
SK Biopharmaceuticals Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 11, 2026.
Company Profile
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.
Community Discussion